Results 1 - 3 of 3

*These authors have contributed equally to this work Correspondence to:

by Ying Wang, Jianguang Zhou, Shanhu Li, Shanhu Li
"... www.impactjournals.com/oncotarget / Oncotarget, Vol. 6, No. 24 PC-1/PrLZ confers resistance to rapamycin in prostate cancer cells through increased 4E-BP1 stability ..."
Abstract - Add to MetaCart
www.impactjournals.com/oncotarget / Oncotarget, Vol. 6, No. 24 PC-1/PrLZ confers resistance to rapamycin in prostate cancer cells through increased 4E-BP1 stability
(Show Context)

Distributed under Creative Commons CC-BY 4.0 OPEN ACCESS

by Nicole Perfito, Esta Sterneck, Denise Chronscinski, Srujana Cherukeri, Fraser Tan, Nicole Perfito, Joelle Lomax, Elizabeth Iorns , 2015
"... Declarations can be found on page 13 DOI 10.7717/peerj.1231 Copyright 2015 Chronscinski et al. ..."
Abstract - Add to MetaCart
Declarations can be found on page 13 DOI 10.7717/peerj.1231 Copyright 2015 Chronscinski et al.

unknown title

by unknown authors
"... Prostate cancer is the most commonly diagnosed non-cutaneous malignancy in men and remains the second-leading cause of cancer-related death in men (1,2). Despite advances in screening for and early detection of prostate ..."
Abstract - Add to MetaCart
Prostate cancer is the most commonly diagnosed non-cutaneous malignancy in men and remains the second-leading cause of cancer-related death in men (1,2). Despite advances in screening for and early detection of prostate